Description

SOR-C13, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 has anticancer activity[1].—Cancer-programmed cell death–C72H116N20O19—-[1]S Fu , et al. Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):397. |[2]Hui Xue, et al. Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. J Cancer. 2018 Aug 6;9(17):3196-3207. –1187852-48-7–1565.81—-O=C(N[C@@H](CCC(O)=O)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CC(C)C)C(N[C@@H](CC2=CNC=N2)C(N3[C@@H](CCC3)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N4[C@@H](CCC4)C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCCN)N–Cancer–10 mM in DMSO–TRP Channel–TRPV–Membrane Transporter/Ion Channel;Neuronal Signaling–Peptides